Eli Lilly and Company (NYSE:LLY) Shares Purchased by Texas Capital Bancshares Inc TX

Texas Capital Bancshares Inc TX boosted its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 1.2% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,771 shares of the company’s stock after buying an additional 21 shares during the period. Eli Lilly and Company accounts for 0.5% of Texas Capital Bancshares Inc TX’s portfolio, making the stock its 29th biggest holding. Texas Capital Bancshares Inc TX’s holdings in Eli Lilly and Company were worth $951,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Norges Bank bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $3,416,206,000. Moneta Group Investment Advisors LLC boosted its position in shares of Eli Lilly and Company by 102,752.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 5,446,026 shares of the company’s stock valued at $1,992,374,000 after purchasing an additional 5,440,731 shares in the last quarter. Morgan Stanley boosted its position in shares of Eli Lilly and Company by 44.1% during the 4th quarter. Morgan Stanley now owns 12,059,204 shares of the company’s stock valued at $4,411,740,000 after purchasing an additional 3,691,436 shares in the last quarter. Imprint Wealth LLC boosted its position in shares of Eli Lilly and Company by 53,716.8% during the 2nd quarter. Imprint Wealth LLC now owns 1,751,200 shares of the company’s stock valued at $175,120,000 after purchasing an additional 1,747,946 shares in the last quarter. Finally, T. Rowe Price Investment Management Inc. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at about $445,944,000. Institutional investors own 81.38% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on LLY shares. Truist Financial raised their price objective on shares of Eli Lilly and Company from $650.00 to $850.00 and gave the company a “buy” rating in a research report on Wednesday, February 7th. Deutsche Bank Aktiengesellschaft started coverage on shares of Eli Lilly and Company in a research note on Thursday, November 9th. They set a “hold” rating and a $535.00 price objective for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, February 20th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Wednesday, November 8th. Finally, DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price objective for the company. in a research note on Wednesday, February 21st. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and an average target price of $663.33.

Check Out Our Latest Stock Analysis on Eli Lilly and Company

Eli Lilly and Company Stock Down 1.0 %

NYSE:LLY traded down $7.36 during mid-day trading on Wednesday, reaching $757.64. The stock had a trading volume of 2,695,328 shares, compared to its average volume of 3,368,917. The business’s 50 day moving average is $662.30 and its 200 day moving average is $605.93. Eli Lilly and Company has a fifty-two week low of $309.20 and a fifty-two week high of $794.47. The stock has a market cap of $719.88 billion, a P/E ratio of 131.47, a PEG ratio of 1.70 and a beta of 0.32. The company has a debt-to-equity ratio of 1.69, a current ratio of 0.94 and a quick ratio of 0.73.

Eli Lilly and Company (NYSE:LLYGet Free Report) last released its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 EPS for the quarter, topping analysts’ consensus estimates of $2.30 by $0.19. Eli Lilly and Company had a return on equity of 51.22% and a net margin of 15.36%. The firm had revenue of $9.35 billion for the quarter, compared to the consensus estimate of $8.95 billion. During the same quarter in the prior year, the company posted $2.09 earnings per share. The firm’s revenue was up 28.1% on a year-over-year basis. As a group, sell-side analysts predict that Eli Lilly and Company will post 12.5 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Thursday, February 15th will be issued a dividend of $1.30 per share. This represents a $5.20 annualized dividend and a yield of 0.69%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s dividend payout ratio (DPR) is 89.66%.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 14,388 shares of the stock in a transaction that occurred on Thursday, January 4th. The stock was sold at an average price of $630.28, for a total transaction of $9,068,468.64. Following the transaction, the insider now owns 99,754,422 shares in the company, valued at $62,873,217,098.16. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have sold a total of 195,055 shares of company stock worth $125,254,657 over the last 90 days. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Featured Articles

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.